Assess
We agree the scope, the question you need answered, and the review cycles included, in writing.
Amia drafts your IND, clinical, and validation documents with AI, then regulatory experts review every finding before it reaches you. Submission-ready work for biotech and pharma teams, without adding headcount.
A four-step model that gets AI into production on your infrastructure, with accountable experts reviewing the work before it reaches you.
We agree the scope, the question you need answered, and the review cycles included, in writing.
A focused pilot proves the workflow on your data before any broader build or commitment.
We build the production system on your infrastructure, with evaluation and monitoring baked in.
We operate, monitor, and improve it: model updates, performance tracking, and expert review on call.
From a multi-billion-dollar bioprocessing leader to a clinical-stage biotech, here is what partners say after putting Amia's work in front of their regulators.
The tool demonstrated strong accuracy against the client’s golden output, including placeholder filling and table population, and showed a reproducible, traceable approach to report generation.
Company and executive identity available to qualified investors under a signed NDA, subject to disclosure authorization.
Amia.ai demonstrated exceptional responsiveness to evolving requirements, rapidly adapted to our specific technical documentation needs, and maintained a collaborative, solutions-oriented team culture throughout the engagement. Their ability to execute and adapt made them a strong technology partner.
Company and executive identity available to qualified investors under a signed NDA, subject to disclosure authorization.
Amia’s MedNova IND gap analysis identified several critical gaps and missing elements that our regulatory writers had overlooked. Without these findings, we could have submitted an IND containing incomplete or inaccurate information, potentially leading to costly delays and additional FDA scrutiny.
MedNova is refreshed weekly to stay current with evolving regulatory requirements and guidance. Company and executive identity available to qualified investors under a signed NDA, subject to disclosure authorization.
Testimonials 1 and 2 are from the same enterprise engagement.
Figures reflect the current industry status quo.
MedNova is Amia’s regulatory analysis platform. It runs the rule checks, retrieves evidence from your documents and public sources, and drafts findings with their sources attached. In our service, you never operate it: an expert reviews every finding before it reaches you.

If an algorithm reads your filing first, have it checked before you send it.
Tell us about your AI initiative or your next filing. We’ll tell you what a scoped engagement would cover and how it would be priced.